Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Benzinga
Covered in this story
Analyst targets on Amgen
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from Benzinga's public RSS feed. The full reporting belongs to Benzinga — please read it on their site.